Developer docs
API playgroundTry for free, no card

Search company profiles

Abscint

Full company profile

uuid000ajpb

Namestring
Abscint
Legal namestring
Abscint nv
Websiteurl
abscint.com
Company typeenum
Private
Founded yearint
2020
Descriptiontext

Abscint is a clinical-stage molecular imaging company developing in-vivo radiopharmaceutical diagnostics based on radiolabeled single-domain antibodies (sdAbs). Founded in 2022 as a spin-off of Vrije Universiteit Brussel (VUB), with research roots at the VIB-VUB Center for Inflammation Research, the company is headquartered in Liège, Belgium (legal entity registered in Ganshoren) and operates with 1–10 employees. Its platform uses 12–15 kDa sdAbs labeled with short-half-life radioisotopes (notably Gallium-68) that bind to specific cell-surface proteins, enabling whole-body PET/CT imaging within 60–90 minutes post-injection with low radiation dose and no patient hospitalization.

The company's lead asset, 68Ga-HER2 (also referenced as ABS011), is a HER2-targeted PET tracer for breast and gastric cancer that visualizes HER2 expression across all lesions, addressing intra-patient heterogeneity missed by single-site biopsies. It is currently in a Phase IIb clinical study (the HERMIA trial) at six Belgian academic centers, with Phase I/II results on 116 patients showing 91% lesion-level agreement with standard IHC/ISH diagnostics and a 34.4% rate of treatment-plan modification. A second pipeline program, ABSCINT-206, targets cardiac sarcoidosis. Abscint's IP rests on a US patent application (16/827,032) with a USPTO Notice of Allowance received in February 2023, licensed from VUB.

Commercially, Abscint is pre-revenue: 68Ga-HER2 has not received marketing authorization in any jurisdiction, and no pricing has been disclosed. Revenue mechanics are currently limited to a GMP-grade precursor access program supplying academic institutes, hospitals, and companies for investigator-initiated trials, with planned future revenue from commercial tracer sales and technology licensing post-approval. Total disclosed funding is approximately EUR 4 million across two rounds in December 2022 and September 2023, led by Noshaq and Qbic with participation from UZ Brussel, Kazoku, Trasis, Wallonie Entreprendre, and family offices.

Short descriptiontext

Abscint is a Belgium-based, clinical-stage spin-off of VUB developing radiolabeled single-domain antibody PET tracers (lead asset 68Ga-HER2 for breast cancer, plus ABSCINT-206 for cardiac sarcoidosis) for whole-body molecular imaging, currently pre-revenue and conducting a Phase IIb HERMIA trial.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersLiège, Belgium
HQ citystring
Liège
HQ countrystring
Belgium
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
molecular imaging diagnostics, PET radiopharmaceuticals, single-domain antibodies, HER2 cancer imaging, radiolabeled diagnostics
Industry2 codes
PRIMARYHLAIAGAA
Diagnostic Radiopharmaceuticals (SPECT/PET Tracers)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
SECONDARYEUAKAIAE
Nuclear Medicine Imaging Tracers & PET/SPECT Supply Chain (FDG, Ga-68, logistics/cold chain)
Energy, Utilities & Environment/Nuclear Energy/Nuclear Materials, Radiation Services & Isotopes (Medical/Industrial)
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing3254
SIC code1 code
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Molecular Imaging Diagnostics
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1GMP Grade Precursor Sales
TypeLicensing Royalties
Description

ABSCINT offers GMP grade precursor to academic institutes, hospitals, and companies for investigator-initiated trials. This represents a potential revenue stream for clinical study access.

abscint.com
2Diagnostic Imaging Products
TypeOne Time License
Description

The company is developing radiopharmaceutical diagnostics for cancer detection, treatment selection, and monitoring. Once regulatory approval is obtained, commercial sales of the PET tracer products will be the primary revenue source.

abscint.com
3Technology Licensing
TypeLicensing Royalties
Description

ABSCINT has licensed patent rights for diagnostic applications from VUB. The company may generate licensing revenue from its HER2 imaging technology platform.

abscint.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Abscint develops radiolabeled single-domain antibody (sdAb) based PET tracers for in-vivo molecular imaging diagnostics. Its lead product, 68Ga-HER2 (ABS011), is a Gallium-68 labeled anti-HER2 PET tracer enabling whole-body imaging of HER2-expressing tumors in breast cancer patients. The company also has a second clinical-stage program, ABSCINT-206, for cardiac sarcoidosis detection, and supplies GMP-grade precursor material to academic institutes and hospitals for investigator-initiated clinical trials.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 34.4% of patients had their treatment plans modified based on HER2 PET/CT results
+3 more records
Product overview1 text field

ABSCINT is a clinical-stage molecular imaging company developing radiopharmaceutical diagnostics based on radiolabeled single-domain antibodies (sdAbs) for whole-body molecular imaging. The company's lead product is 68Ga-HER2 (ABS011), a PET tracer for HER2 imaging in breast cancer, currently in Phase IIb clinical trials through the HERMIA study. ABSCINT also has a second clinical-stage program, ABSCINT-206, for cardiac sarcoidosis detection. The company offers a GMP precursor access program enabling investigator-initiated trials. The technology platform uses single-domain antibodies (12-15 kDa) labeled with short-half-life radioisotopes (such as gallium-68) for precise, whole-body imaging within 60-90 minutes post-injection, enabling diagnosis, treatment selection, and treatment response monitoring.

Product and service3 records
168Ga-HER2 (ABS011)
CategoryRadiopharmaceutical PET Tracer
2ABSCINT-206
CategoryRadiopharmaceutical PET Tracer
3GMP Precursor Access Program
CategoryClinical Trial Services
Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
1Institut Jules Bordet
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2023-09-26
Description

Leading Belgian cancer research institute and clinical trial site. Participating in HERMIA clinical trial evaluating 68Ga-ABS011 PET/CT in breast cancer patients. Located in Anderlecht, Belgium.

abscint.com
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2023-09-26
Description

University Hospital Brussels with 3,800+ staff and 721 beds. Clinical trial site for HERMIA study and investor in ABSCINT. Research partner with teaching mission connected to VUB.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2023-09-26
Description

University Hospitals Leuven, major Belgian academic medical center. Clinical trial site for HERMIA study evaluating ABSCINT-HER2 imaging technology.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-12-05
Description

ABSCINT is a spin-off from VUB. Technology based on joint research efforts of Prof. Dr. Tony Lahoutte at VUB and Prof. Dr. Jo Van Ginderachter at VIB-VUB Center for Inflammation Research. VUB licensed patent for diagnostic applications to ABSCINT.

5VIB
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-12-05
Description

VIB is an independent research institute where top scientists conduct pioneering basic research. Joint research efforts with VUB team of Prof. Jo Van Ginderachter at VIB-VUB Center for Inflammation Research contributed to ABSCINT's technology platform.

abscint.com
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Precirix develops single-domain antibody (sdAb)-based radiopharmaceuticals for cancer imaging, including HER2-targeted and other oncology tracers. It is the most direct technology peer to Abscint, using the same camelid sdAb scaffold and a similar radiolabeling approach for PET imaging.

TypeDirect peer
Description

ImaginAb is a clinical-stage immuno-imaging company using camelid single-domain antibodies (nanobodies) to develop diagnostic imaging agents for oncology, immunology, and other diseases. Direct peer based on shared sdAb platform and PET/SPECT imaging focus.

TypeBroad incumbent
Description

Telix is a commercial-stage radiopharmaceutical company with multiple approved and late-stage imaging products (e.g., Illuccix for PSMA PET) and a growing theranostic pipeline. It competes broadly in the molecular imaging space and represents the kind of scaled player AbscINT would need to position against in HER2 imaging.

TypeBroad incumbent
Description

Lantheus is an established radiopharmaceutical company with commercial diagnostic products (e.g., Pylarify for PSMA PET imaging) and a growing pipeline. Comparable as a broad incumbent in radiodiagnostics with similar end-customer focus on hospital nuclear medicine departments.

TypeBroad incumbent
Description

Curium is one of the largest nuclear medicine companies globally, producing and distributing SPECT and PET radiopharmaceuticals across a broad portfolio. Comparable as a large incumbent supplying diagnostic tracers to hospital networks that Abscint also targets.

TypeBroad incumbent
Description

GE HealthCare is a global medical imaging and nuclear medicine leader, including PET radiotracer production (e.g., 18F-FDG) and a broad portfolio of molecular imaging agents. Broad incumbent comparable on the nuclear medicine / PET imaging value chain that Abscint's tracers plug into.

TypeBroad incumbent
Description

Bracco Imaging is a global diagnostic imaging company offering contrast agents and radiopharmaceuticals for MRI, CT, ultrasound, and nuclear medicine. Broad incumbent with overlapping end customers (hospitals, imaging centers) where Abscint's HER2 PET tracer would be administered.

TypeEmerging player
Description

Ratio Therapeutics is an emerging radiopharmaceutical company developing targeted radioconjugates for both imaging and therapy in oncology. Comparable as a smaller, earlier-stage peer operating in the same radiopharmaceutical space with potential overlap in HER2 and other oncology targets.

TypeOthers
Description

Cardinal Health operates one of the largest radiopharmaceutical distribution networks in the US, supplying unit-dose radiopharmaceuticals to hospitals and clinics. Comparable as a key distribution/infrastructure channel in the radiopharma value chain that Abscint's products would rely on for US scaling.

TypeOthers
Description

Novartis commercializes the radioligand therapies Lutathera and Pluvicto and is investing heavily in radioligand imaging companion diagnostics. Comparable as an adjacent incumbent shaping the broader radioligand diagnostic/theranostic landscape in which Abscint's HER2 imaging technology sits.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Abscint

Molecular Imaging Diagnosticsabscint.com

Abscint is a Belgium-based, clinical-stage spin-off of VUB developing radiolabeled single-domain antibody PET tracers (lead asset 68Ga-HER2 for breast cancer, plus ABSCINT-206 for cardiac sarcoidosis) for whole-body molecular imaging, currently pre-revenue and conducting a Phase IIb HERMIA trial.

What Abscint does

Abscint is a clinical-stage molecular imaging company developing in-vivo radiopharmaceutical diagnostics based on radiolabeled single-domain antibodies (sdAbs). Founded in 2022 as a spin-off of Vrije Universiteit Brussel (VUB), with research roots at the VIB-VUB Center for Inflammation Research, the company is headquartered in Liège, Belgium (legal entity registered in Ganshoren) and operates with 1–10 employees. Its platform uses 12–15 kDa sdAbs labeled with short-half-life radioisotopes (notably Gallium-68) that bind to specific cell-surface proteins, enabling whole-body PET/CT imaging within 60–90 minutes post-injection with low radiation dose and no patient hospitalization.

The company's lead asset, 68Ga-HER2 (also referenced as ABS011), is a HER2-targeted PET tracer for breast and gastric cancer that visualizes HER2 expression across all lesions, addressing intra-patient heterogeneity missed by single-site biopsies. It is currently in a Phase IIb clinical study (the HERMIA trial) at six Belgian academic centers, with Phase I/II results on 116 patients showing 91% lesion-level agreement with standard IHC/ISH diagnostics and a 34.4% rate of treatment-plan modification. A second pipeline program, ABSCINT-206, targets cardiac sarcoidosis. Abscint's IP rests on a US patent application (16/827,032) with a USPTO Notice of Allowance received in February 2023, licensed from VUB.

Commercially, Abscint is pre-revenue: 68Ga-HER2 has not received marketing authorization in any jurisdiction, and no pricing has been disclosed. Revenue mechanics are currently limited to a GMP-grade precursor access program supplying academic institutes, hospitals, and companies for investigator-initiated trials, with planned future revenue from commercial tracer sales and technology licensing post-approval. Total disclosed funding is approximately EUR 4 million across two rounds in December 2022 and September 2023, led by Noshaq and Qbic with participation from UZ Brussel, Kazoku, Trasis, Wallonie Entreprendre, and family offices.

Abscint firmographics

Firmographics
Name
Abscint
Legal name
Abscint nv
Website
https://abscint.com
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
1–10 employees
Short description
Abscint is a Belgium-based, clinical-stage spin-off of VUB developing radiolabeled single-domain antibody PET tracers (lead asset 68Ga-HER2 for breast cancer, plus ABSCINT-206 for cardiac sarcoidosis) for whole-body molecular imaging, currently pre-revenue and conducting a Phase IIb HERMIA trial.
Ownership category
akta.pro rank

Abscint industry classification

Industry
Product category
Molecular Imaging Diagnostics
NAICS
Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)
SIC
In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAIAGAA
Diagnostic Radiopharmaceuticals (SPECT/PET Tracers)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
SECONDARYEUAKAIAE
Nuclear Medicine Imaging Tracers & PET/SPECT Supply Chain (FDG, Ga-68, logistics/cold chain)
Energy, Utilities & Environment/Nuclear Energy/Nuclear Materials, Radiation Services & Isotopes (Medical/Industrial)

Keywords

  • Molecular imaging diagnostics
  • PET radiopharmaceuticals
  • Single-domain antibodies
  • HER2 cancer imaging
  • Radiolabeled diagnostics

Where Abscint is headquartered

Location

Headquarters

HQ city
Liège
HQ country
Belgium
HQ region
Europe

Offices1 record

Markets served

Abscint business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Others

Revenue model

  1. GMP Grade Precursor Sales: ABSCINT offers GMP grade precursor to academic institutes, hospitals, and companies for investigator-initiated trials. This represents a potential revenue stream for clinical study access.
  2. Diagnostic Imaging Products: The company is developing radiopharmaceutical diagnostics for cancer detection, treatment selection, and monitoring. Once regulatory approval is obtained, commercial sales of the PET tracer products will be the primary revenue source.
  3. Technology Licensing: ABSCINT has licensed patent rights for diagnostic applications from VUB. The company may generate licensing revenue from its HER2 imaging technology platform.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Abscint product offering

Product offering

Core offering

Abscint develops radiolabeled single-domain antibody (sdAb) based PET tracers for in-vivo molecular imaging diagnostics. Its lead product, 68Ga-HER2 (ABS011), is a Gallium-68 labeled anti-HER2 PET tracer enabling whole-body imaging of HER2-expressing tumors in breast cancer patients. The company also has a second clinical-stage program, ABSCINT-206, for cardiac sarcoidosis detection, and supplies GMP-grade precursor material to academic institutes and hospitals for investigator-initiated clinical trials.

Product overview

ABSCINT is a clinical-stage molecular imaging company developing radiopharmaceutical diagnostics based on radiolabeled single-domain antibodies (sdAbs) for whole-body molecular imaging. The company's lead product is 68Ga-HER2 (ABS011), a PET tracer for HER2 imaging in breast cancer, currently in Phase IIb clinical trials through the HERMIA study. ABSCINT also has a second clinical-stage program, ABSCINT-206, for cardiac sarcoidosis detection. The company offers a GMP precursor access program enabling investigator-initiated trials. The technology platform uses single-domain antibodies (12-15 kDa) labeled with short-half-life radioisotopes (such as gallium-68) for precise, whole-body imaging within 60-90 minutes post-injection, enabling diagnosis, treatment selection, and treatment response monitoring.

Differentiator

Problem solved

Functional benefit

Products and services

  • 68Ga-HER2 (ABS011)
  • ABSCINT-206
  • GMP Precursor Access Program

Quantifiable outcome

  • 34.4% of patients had their treatment plans modified based on HER2 PET/CT results
  • +3 more outcomes

Companies that use Abscint

Customer profile

Named customers4 records

Segments3 records

Ideal customer profiles2 records

Abscint technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Abscint partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered major and core.

  • Institut Jules BordetmajorStrategic or Co-development Partner · 26 September 2023Leading Belgian cancer research institute and clinical trial site. Participating in HERMIA clinical trial evaluating 68Ga-ABS011 PET/CT in breast cancer patients. Located in Anderlecht, Belgium.
  • UZ BrusselmajorStrategic or Co-development Partner · 26 September 2023University Hospital Brussels with 3,800+ staff and 721 beds. Clinical trial site for HERMIA study and investor in ABSCINT. Research partner with teaching mission connected to VUB.
  • UZ LeuvenmajorStrategic or Co-development Partner · 26 September 2023University Hospitals Leuven, major Belgian academic medical center. Clinical trial site for HERMIA study evaluating ABSCINT-HER2 imaging technology.
  • Vrije Universiteit Brussel (VUB)coreStrategic or Co-development Partner · 5 December 2022ABSCINT is a spin-off from VUB. Technology based on joint research efforts of Prof. Dr. Tony Lahoutte at VUB and Prof. Dr. Jo Van Ginderachter at VIB-VUB Center for Inflammation Research. VUB licensed patent for diagnostic applications to ABSCINT.
  • VIBcoreStrategic or Co-development Partner · 5 December 2022VIB is an independent research institute where top scientists conduct pioneering basic research. Joint research efforts with VUB team of Prof. Jo Van Ginderachter at VIB-VUB Center for Inflammation Research contributed to ABSCINT's technology platform.

Scale indicators5 records

Recent moves7 records

Expansion highlights6 records

Abscint competitors and assessment

Company assessment

Direct peers

  • Precirix: Precirix develops single-domain antibody (sdAb)-based radiopharmaceuticals for cancer imaging, including HER2-targeted and other oncology tracers. It is the most direct technology peer to Abscint, using the same camelid sdAb scaffold and a similar radiolabeling approach for PET imaging.
  • ImaginAb: ImaginAb is a clinical-stage immuno-imaging company using camelid single-domain antibodies (nanobodies) to develop diagnostic imaging agents for oncology, immunology, and other diseases. Direct peer based on shared sdAb platform and PET/SPECT imaging focus.

Broad incumbents

  • Telix Pharmaceuticals: Telix is a commercial-stage radiopharmaceutical company with multiple approved and late-stage imaging products (e.g., Illuccix for PSMA PET) and a growing theranostic pipeline. It competes broadly in the molecular imaging space and represents the kind of scaled player AbscINT would need to position against in HER2 imaging.
  • Lantheus Holdings: Lantheus is an established radiopharmaceutical company with commercial diagnostic products (e.g., Pylarify for PSMA PET imaging) and a growing pipeline. Comparable as a broad incumbent in radiodiagnostics with similar end-customer focus on hospital nuclear medicine departments.
  • Curium Pharma: Curium is one of the largest nuclear medicine companies globally, producing and distributing SPECT and PET radiopharmaceuticals across a broad portfolio. Comparable as a large incumbent supplying diagnostic tracers to hospital networks that Abscint also targets.
  • GE HealthCare: GE HealthCare is a global medical imaging and nuclear medicine leader, including PET radiotracer production (e.g., 18F-FDG) and a broad portfolio of molecular imaging agents. Broad incumbent comparable on the nuclear medicine / PET imaging value chain that Abscint's tracers plug into.
  • Bracco Imaging: Bracco Imaging is a global diagnostic imaging company offering contrast agents and radiopharmaceuticals for MRI, CT, ultrasound, and nuclear medicine. Broad incumbent with overlapping end customers (hospitals, imaging centers) where Abscint's HER2 PET tracer would be administered.

Emerging players

  • Ratio Therapeutics: Ratio Therapeutics is an emerging radiopharmaceutical company developing targeted radioconjugates for both imaging and therapy in oncology. Comparable as a smaller, earlier-stage peer operating in the same radiopharmaceutical space with potential overlap in HER2 and other oncology targets.

Others

  • Cardinal Health Nuclear & Precision Health Solutions: Cardinal Health operates one of the largest radiopharmaceutical distribution networks in the US, supplying unit-dose radiopharmaceuticals to hospitals and clinics. Comparable as a key distribution/infrastructure channel in the radiopharma value chain that Abscint's products would rely on for US scaling.
  • Novartis (Radioligand Therapy franchise): Novartis commercializes the radioligand therapies Lutathera and Pluvicto and is investing heavily in radioligand imaging companion diagnostics. Comparable as an adjacent incumbent shaping the broader radioligand diagnostic/theranostic landscape in which Abscint's HER2 imaging technology sits.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Abscint social profiles

Digital presence

Abscint financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Abscint leadership team

Management profile

Number of profiles

Profiles7 records

Abscint funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Abscint M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Abscint

What does Abscint do?

Abscint develops radiolabeled single-domain antibody (sdAb) based PET tracers for in-vivo molecular imaging diagnostics. Its lead product, 68Ga-HER2 (ABS011), is a Gallium-68 labeled anti-HER2 PET tracer enabling whole-body imaging of HER2-expressing tumors in breast cancer patients. The company also has a second clinical-stage program, ABSCINT-206, for cardiac sarcoidosis detection, and supplies GMP-grade precursor material to academic institutes and hospitals for investigator-initiated clinical trials.

Is Abscint a public or private company?

Abscint is a private company. It is classified as venture growth investor backed and is currently operating.

When was Abscint founded?

Abscint was founded in 2020. It employs 1 to 10 people.

Where is Abscint based?

Abscint is headquartered in Liège, Belgium, in the Europe region.

How does Abscint make money?

Three revenue lines are on record. GMP Grade Precursor Sales are the primary driver. The others are diagnostic Imaging Products and technology Licensing.

Who are Abscint's main competitors?

Direct peers on record are Precirix and ImaginAb. Broad incumbents are Telix Pharmaceuticals, Lantheus Holdings, Curium Pharma, GE HealthCare and Bracco Imaging. Ratio Therapeutics is listed as an emerging player. Others are Cardinal Health Nuclear & Precision Health Solutions and Novartis (Radioligand Therapy franchise).

Does Abscint have an API?

No public API is recorded for Abscint.

What industry is Abscint in?

Abscint's product category is Molecular Imaging Diagnostics. Its primary akta.pro industry code is HLAIAGAA, Diagnostic Radiopharmaceuticals (SPECT/PET Tracers), with a secondary code of EUAKAIAE, Nuclear Medicine Imaging Tracers & PET/SPECT Supply Chain (FDG, Ga-68, logistics/cold chain). Its NAICS code is 325412 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals